Lentiviral mediated gene therapy combined with optimized HSC mobilization and transduction protocols has been successfully used to treat HSCs from FANCA-deficient (FA-A) patients, the most prevalent FA complementation group12,13. This evidence concerns the gene FANCA and Friedreich ataxia.